| 0 (0%) | 05-29 17:28 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.6  |
1-year : | 5.37 |
| Resists | First : | 3.94 |
Second : | 4.6 |
| Pivot price | 3.08 |
|||
| Supports | First : | 2.86 |
Second : | 2.2 |
| MAs | MA(5) : | 3.39 |
MA(20) : | 3.08 |
| MA(100) : | 2.76 |
MA(250) : | 3.42  |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 86.6 |
D(3) : | 79.8 |
| RSI | RSI(14): 71.7 |
|||
| 52-week | High : | 6.59 | Low : | 2.15 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BLRX ] has closed above the upper band by 8.6%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 130% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.94 - 3.95 | 3.95 - 3.97 |
| Low: | 3.42 - 3.44 | 3.44 - 3.45 |
| Close: | 3.76 - 3.78 | 3.78 - 3.8 |
Fri, 29 May 2026
BioLineRx (BLRX) Q1 2026 Earnings Transcript - The Globe and Mail
Fri, 29 May 2026
BioLineRx shares advance after first patient enrolled in GLIX1 cancer study (BLRX) - MSN
Thu, 28 May 2026
BLRX: First Quarter 2026 Results - Yahoo Finance
Wed, 27 May 2026
BLRX: GLIX1 clinical trial launched for GBM, APHEXDA sales and royalties up, cash runway into 2027 - TradingView
Wed, 27 May 2026
BLRX: GLIX1 clinical trial launch and APHEXDA sales growth drive revenue and R&D expansion - TradingView
Wed, 27 May 2026
GLIX1 first patient dosed as BioLineRx (NASDAQ: BLRX) flags going concern risk - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 2.5e+009 (%) |
| Held by Institutions | 3.9 (%) |
| Shares Short | 164 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.006e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -99.6 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 745.3 % |
| Return on Equity (ttm) | -16.2 % |
| Qtrly Rev. Growth | 1.18e+006 % |
| Gross Profit (p.s.) | -166.62 |
| Sales Per Share | -18.67 |
| EBITDA (p.s.) | 1.61017e+006 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.21 |
| Price to Cash Flow | 0.53 |
| Dividend | 0 |
| Forward Dividend | 157500 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|